CD274 and non-small cell lung carcinoma: The Morpheus study compared objective remission rates and safety of second-line therapy with atezolizumab plus CPI-444 and docetaxel in NSCLC patients who showed disease progression during or after treatment with platinum-based regimens and PD-L1/PD-1 checkpoint inhibitors (76).